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In search for new anticancer agents, we have evaluated the antiinvasive and antimigrative properties of recently developed synthetic
coumarin derivatives among which two compounds revealed important activity: 3-chlorophenyl 6-acetoxymethyl-2-oxo-2H-1-
benzopyran-3-carboxylate and 3-bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate. Both drugs were able to
inhibit cell invasion markedly in a Boyden chamber assay, the bromo derivative being more potent than the reference matrix
metalloprotease (MMP) inhibitor GI 129471. In vivo, tumour growth was reduced when nude mice grafted with HT1080 or MDA-
MB231 cells were treated i.p. 3 days week
 1 with the bromo coumarin derivative. These effects were not associated with the
inhibition of urokinase, plasmin, MMP-2 or MMP-9. The mechanism of action of the drugs remains to be elucidated. However, these
two coumarin derivatives may serve as new lead compounds of an original class of antitumour agents.
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The process of cancer invasion is a multistep event involving
angiogenesis, local invasion, cell migration, dissemination and
growth at a secondary site (Zetter, 1998). During malignant
transformation, tumour cells have to acquire new functions such
as self-sufficiency in growth signals, insensitivity to growth-
inhibitory (antigrowth) signals, resistance to apoptosis, adhesive
and invasive capacities (Hanahan and Weinberg, 2000). Basement
membrane provides a main physical barrier to cell migration at
different steps of this metastatic process: escape from the primary
tumour in carcinomas, intravasation and extravasation during
haematogenous dissemination. Invasion of basement membranes
involves: (i) the adhesion of tumour cells via cell surface
molecules, (ii) secretion of proteolytic enzymes including at least
serine proteases and matrix metalloproteases (MMPs) and (iii) cell
migration into target tissue in response to specific chemotactic
stimuli (Liotta, 1986; Stetler-Stevenson et al, 1993; Hanahan and
Weinberg, 2000). In addition, the acquisition of invasive properties
by some tumour cells is associated with the alteration of several
classes of proteins involved in cell–cell and cell–matrix interac-
tions. These affected proteins include at least members of the
immunoglobulin and calcium-dependent cadherin families and
integrins (Hanahan and Weinberg, 2000). The proteolytic event
induced by proteases allows the invasion of cancer cells locally and
at distance, as well as the release or the activation of growth or
angiogenic factors (for review, see Frankenne et al, 1999; Noe ¨l et al,
1999; Schmitt et al, 2000; Egeblad and Werb, 2002).
By using the Boyden chamber assay, we have evaluated different
coumarin derivatives as anti-invasive compounds and analysed
their inhibitory activity against some serine proteases and MMPs.
In previous works, we have investigated a series of original
coumarin derivatives (6-substituted 2-oxo-2H-1-benzopyran-3-
carboxylic acid analogues). Some of them were potent inhibitors
of serine proteases such as a-chymotrypsin (a-CT), human
leucocyte elastase (HLE) and thrombin (THR) (Pochet et al,
1996, 2000; Doucet et al, 1999). Based on the invasive assay, among
eight coumarin derivatives evaluated, we have selected two
compounds, 3-chlorophenyl 6-acetoxymethyl-2-oxo-2H-1-benzo-
pyran-3-carboxylate (compound 4) and 3-bromophenyl 6-acetoxy-
methyl-2-oxo-2H-1-benzopyran-3-carboxylate (compound 7)
(Figure 1), which were further examined for their ability to affect
the tumorigenicity in vivo of human fibrosarcoma and human
breast adenocarcinoma cells. Their inhibitory potency against
different serine proteases and MMPs was also determined. We
provide evidence that these two coumarin derivatives display
interesting and important in vivo antitumour effect.
MATERIALS AND METHODS
Chemistry
Melting points were determined on a Bu ¨chi-Tottoli capillary
apparatus and are uncorrected. Infrared spectra were recorded as
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sKBr pellets on a Perkin-Elmer 1750 FT spectrophotometer. The
1H
nuclear magnetic resonance spectra were taken on a Bruker AW-80
(80MHz) instrument in dimethyl-d6 sulphoxide with hexamethyl
disilazane as an internal standard; chemical shifts are reported in d
values (p.p.m.) relative to internal HMDS. The abbreviations s
(¼singlet), d (¼doublet) and m (¼multiplet) are used through-
out. Elemental analyses (C, H) were realised on a Carlo-Erba EA
1108-elemental analyser and were within 70.4% of the theoretical
values. All reactions were routinely checked by thin layer
chromatography on silica gel Merck 60F 254.
Synthetic coumarin derivatives
The coumarin derivatives were obtained according to previously
described synthetic procedures (Pochet et al, 1996, 2000). The
physicochemical and spectral data of the new derivatives 6, 7 and 8
are reported in Tables 1 and 2.
Cell culture
Human fibrosarcoma HT1080 cells and human breast MDA-MB
231 adenocarcinoma cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (vv
 1) fetal calf
serum (FCS), penicillin–streptomycin (100IUml
 1; 100mgml
 1),
2m M glutamine and 10mM HEPES buffer at 371C in a humid
atmosphere (5% CO2 and 95% O2).
Coating of culture wells with type IV collagen
Plates (24-well) (Falcon, Becton-Dickinson, USA) and 6.5mm
polycarbonate filters (8mm pore size) of Transwell cell culture
chamber inserts (Costar, Netherlands) were coated with 100mlo f
type IV collagen purified from human placenta diluted at
200mgml
 1 in phosphate-buffered saline (PBS). Coats were left
to air-dry overnight in a laminar flow hood under UV light.
Uniformity of the coating was assessed by Coomassie blue
staining. Before use, coated plates and inserts were washed twice
with water and incubated for at least 1h in serum-free DMEM at
371C (Maquoi et al, 1999).
Invasion assay
HT1080 cells exponentially growing in T-75 flasks (Nunc, Costar,
Netherlands) were collected by trypsin–ethylenediaminetetraacetic
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Figure 1 Chemical structure of the coumarin derivatives.
Table 1 Physicochemical data of the coumarin derivatives 6–8
Compound
Melting point
(1C) Yield (%)
Molecular
formula
6 170–172 53 C19H13FO6
7 141–142 55 C19H13BrO6
8 169–170 57 C19H13IO6
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sacid treatment, washed with serum-containing medium and
allowed to recover from trypsinisation for at least 30min at
371C. Cells were then washed twice in serum-free DMEM and
diluted in the same medium supplemented with 0.1% bovine
serum albumin (BSA, fraction V, Sigma, USA) to a cell density of
6 10
5 cellsml
 1.
The influence of coumarin derivatives (0.1, 1 and 10mM)o n
HT1080 cell invasion and migration was assayed using Transwell cell
culture inserts (Costar) and compared to the reference compound GI
129471 (1mM), an MMP inhibitor (Wheeler et al, 1998).
For chemoinvasion assays, type IV collagen-coated membranes
(see above) were used, whereas uncoated membranes were
employed for chemotaxis assays. Lower wells of chambers were
filled with DMEM supplemented with 20% FCS and 1% BSA
(fraction V, ICN) as chemoattractant, in the presence or absence of
coumarin derivative (final concentration 0.1, 1 and 10mM)o rG I
129471 (final concentration 1mM). Cells (6 10
4) suspended in
DMEM supplemented with 0.1% BSA (fraction V, ICN) were
seeded in the upper wells. Chambers were subsequently incubated
for 48 and 4h for chemoinvasion and chemotaxis assays,
respectively, in a humid atmosphere at 371C (in order to maintain
a chemotactic gradient, media from both lower and upper wells
were renewed after 24h). After incubation, filters were removed
from the chambers, fixed in 4% paraformaldehyde for 15min
(41C), permeabilised for 10min in methanol ( 201C) and stained
with Giemsa (4%) for 15min. The upper surface of the filters was
scrapped with a cotton swab and cells having reached the lower
surface of the filters were visually counted using a light microscope
(Vanox AH3, Olympus, Hamburg, Germany) at 20-fold magnifica-
tion. Each assay was performed in triplicate. Results were
expressed as percentages (7s.d.) of the migration of control cells.
Cytotoxicity assay
In order to assess the potential influence of coumarin derivatives
(0.1, 1 and 10mM) on cell metabolism, HT1080 cell suspension
(6 10
5 cellsml
 1) was plated on type IV collagen-coated 96-well
plates, 200mlwell
 1 (1.2 10
5 cells), in the same culture conditions
as described above and incubated for 48h in the presence of
different concentrations of the coumarin derivative (medium
renewal occurred after 24h). Media were subsequently harvested
and replaced by 100ml of DMEM supplemented with 10% WST-1
(4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-ben-
zene disulphonate, Boehringer Mannheim, Germany) and plates
were incubated for 2h at 371C. Cellular metabolism was
determined by measuring the absorbance of the medium between
420 and 480nm (with a reference filter of 595nm) on a microtitre
plate reader (Multiscan MS, Labsystems, Finland). At the
concentrations tested, the synthetic coumarin derivatives did not
significantly affect cellular metabolism (data not shown).
Proliferation and adhesion assays
Cells (6.8 10
4 for proliferation assay and 1 10
5 for adhesion
assay) were plated on plastic or type IV collagen or matrigel in
24-well plates (Falcon, Becton Dickinson, USA). At each time points
(2h, 4h, 7h 30min and 23h for the adhesion assay; days 1, 2, 5 and
7 for proliferation assay), the medium was removed, and the cells
were washed with PBS and frozen at  201C. The DNA content was
determined by spectrofluorimetry (Crescimano et al,1 9 9 6 ) .F o rc e l l
adhesion, the DNA content of the initial cell suspension was
considered as 100%. Each assay was performed in triplicate.
In vivo studies
Matrigel (basement membrane proteins) was extracted from the
mouse Engelbreth–Holm–Swarm (EHS) tumour as previously
described (Noe ¨l et al, 1991). Tumoral cells were detached by
trypsinisation, harvested by centrifugation, resuspended in 0.25ml
of serum-free medium and mixed with an equal volume of cold
matrigel (10mgml
 1). The suspension (1 10
6cellsinjection
site
 1) was injected subcutaneously (s.c.) on both body flanks of
6–8-week-old female athymic nude mice (n¼6; nu/nu Swiss mice
from Iffa credo, L’Arbresle, France). The coumarin derivatives in
PBS were injected intraperitoneally (30mgkg
 1) three times per
week during the whole assay.
Animals received human care, and experiments have been
carried out with ethical committee approval. The ethical guidelines
that were followed meet the standards required by the UKCCCR
guidelines (Workman et al, 1998).
The tumorigenicity defines the capacity of cells to induce
tumour formation. The larger (a) and smaller (b) diameters of the
apparent tumour were measured and served for tumour volume
calculation according to a b
2 0.4 (Attia and Weiss, 1966).
Injected mice were examined weekly. Tumours presenting a
volume higher than 80mm
3 and which maintained a progressive
growth were taken into account (Noe ¨l et al, 1992). Results are
expressed as the mean (7s.e.m.) of the tumour volumes.
Sodium dodecyl sulphate – polyacrylamide gel
electrophoresis and zymography
The culture medium of human fibrosarcoma HT1080 cells
(DMEM) was removed and concentrated 20-fold in a Vivaspin
6ml concentrator. It was incubated for 30min at ambient
temperature in nonreducing sample buffer and run under Laemmli
conditions (Laemmli, 1970) by loading a volume of 25ml onto 7.5%
polyacrylamide gels containing 0.1% sodium dodecyl sulphate
(SDS), 2mgml
 1 casein and 0.16mM human plasminogen. Follow-
ing electrophoresis, gels were incubated for 1h in 2.5% (vv
 1)
Triton X-100 for removal of SDS and then for 1h at 371Ci n5 0m M
Tris-HCl, 0.1 M NaCl, pH 7.6. Plasminogen activator (PA) activity
was visualised as clear bands of lysis upon staining with 0.1%
Coomassie blue R250. Purified human high-molecular-weight two-
chain urokinase plasminogen activator (HMW-uPA) and low-
molecular-weight urokinase plasminogen activator (LMW-uPA)
were run in each gel as positive controls. An analogous protocol
was followed to detect enzymatic activities towards MMP-2 and
MMP-9 except that the 7% SDS–PAGE contained 1mgml
 1
bovine gelatin. The gels were incubated at 371C for about 18h in
Table 2 Spectral data of the coumarin derivatives 6–8
Compound IR (KBr) (cm
 1)
1H NMR (80MHz, DMSO-d6, HMDS) d (p.p.m.)
6 3066 (C–H aromatic); 1735 (C=O ester and lactone);
1629; 1580; 1486; 1363; 1247
2.05 (s, 3H, CH3), 5.1 (s, 2H, CH2), 7–7.95
(m, 7H, 5-H, 7-H, 8-H, 20-H, 40-H, 50-H, 60-H), 9.0 (s, 1H, 4-H)
7 3070 (C–H aromatic); 1735 (C=O ester and lactone);
1628; 1579; 1470; 1367; 1246
2.0 (s, 3H, CH3), 5.15 (s, 2H, CH2), 7.25–7.95
(m, 7H, 5-H, 7-H, 8-H, 20-H, 40-H, 50-H, 60-H), 9.0 (s, 1H, 4-H)
8 3065 (C–H aromatic); 1762 (C=O ester);
1722 (C=O lactone); 1623; 1575; 1466; 1376; 1248
2.1 (s, 3H, CH3), 5.1 (s, 2H, CH2), 7.15–7.9
(m, 7H, 5-H, 7-H, 8-H, 20-H, 40-H, 50-H, 60-H), 8.95 (s, 1H, 4-H)
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s5m M Tris, pH 7.6 containing 0.2 M NaCl, 5mM CaCl2 and 0.02
(wv
 1) Brij35. Protein staining was performed during 1h with a
0.25% solution of Coomassie brillant blue R250 in 50% methanol
and 7% acetic acid and destaining in a solution of 20% methanol
and 50% acetic acid. Purified pro-MMP-2, pro-MMP-9 and MMP-2
were used as positive controls. MMP-2 was freshly prepared by
incubating pro-MMP-2 with 100mM p-aminophenylmercuric acet-
ate (APMA, dissolved in 50mM Tris) for 30min at 371C. Some
experiments were carried out with the culture medium after
activation by 100mM APMA (30min at 371C). The effects of
compounds 4 and 7 (1–100mM) incubated in the culture medium
were checked for both types of zymography.
Enzymatic studies
Bovine a-CT and LMW-uPA (MW¼33000Da) were purchased
from Sigma, HMW-uPA (MW¼54000Da) from Choay, trypsin
(TRY) and THR from Boehringer-Indelheim (Germany), and
MMP-2 and MMP-9 from Calbiochem. Human leucocyte elastase
and PM were from Elastase Products Co. and Biogenic, respec-
tively. Except for THR, HMW-uPA, MMP-2 and MMP-9, enzyme
concentrations were determined by active-site titrations using the
appropriate titrant (Bender et al, 1966; Chase and Shaw, 1970;
Powers and Gupton, 1977). Several enzymes were assayed
spectrophotometrically at 405nm using the following p-nitroani-
lide substrates: succininyl-Ala2-Pro-Phe-p-nitroanilide (Suc-
AAPF-p-NA), benzoyl-Arg-p-nitroanilide (Bz-R-p-NA) and meth-
oxysuccinyl-Ala2-Pro-Val-p-nitroanilide (MeO-Suc-AAPV-p-NA)
for a-CT, TRY and HLE, respectively (obtained from Sigma); or
S-2238 (H-D-Ile-Pro-Arg-p-nitroanilide), S-2444 (oGlu-Gly-Arg-
p-nitroanilide) and S-2251 (H-D-Val-Leu-Lys-p-nitroanilide) for
THR, HMW- and LMW-uPA, and PM, respectively (from
Biogenic). Matrix metalloprotease-2 previously activated by
treatment with APMA were assayed at 412nm with the thiopeptide
Ac-Pro-Leu-Gly-
Sleu-Leu-Gly-Oet in the presence of 5,50-dithio-
bis(2-nitrobenzenic) acid (DTNB). The amidolytic activities of the
enzymes were followed in 0.025 M sodium phosphate, 0.05KCl, pH
7.5 for a-CT; 0.1 M HEPES, 0.5 M NaCl, 0.1% (vv
 1) Tween 80, pH
8.0 for HLE; 0.01 M HEPES, 0.01 M Tris, 0.1 M NaCl, 0.1% (vv
 1)
PEG6000, pH 7.5 for THR; 0.1 M Tris, 0.01 M CaCl2, pH 7.5 for TRY;
0.025 M NaH2PO4, 0.1 M NaCl, 0.05% (vv
 1) Tween 80, pH 7.5 for
HMW-and LMW-uPA; 0.1 M NaH2PO4, 25% (vv
 1) glycerol, pH
7.5 for PM; and 0.1 M Tris, 0.15 M NaCl, 0.01 M CaCl2, 0.005%
(ww
 1) NaN3, 0.03% (ww
 1) Brij35, pH 7.5 for MMP-2 and MMP-
9. All assays contained 10% (vv
 1) DMSO and were run at 251Ci n
a Perkin-Elmer Lambda 5 or Kontron Uvikon 941 spectro-
photometer equipped with a thermostated cell holder.
The kinetic parameters for the inhibition were determined either
by the preincubation method for LMW-uPA and PM (small
aliquots of the reaction mixture were withdrawn at intervals of
time and the remaining activity determined), or by the progress
curve method (HLE) when the inhibition was too fast to be
measured accurately using the preincubation method. The
minimum kinetic scheme for the inactivation process is described
as follows:
E þ IÐ
KI
E   I!
ki E-I0 ð1Þ
where E is the enzyme, E*I a kinetic chimere of the Michaelis
complex and the acyl-enzyme, E-I0 the inactivated enzyme, KI the
apparent enzyme-inhibitor dissociation constant and ki the
inactivation rate constant at infinite inhibitor concentration. Using
the preincubation method, the pseudo-first-order constants for
inactivation kobs were obtained from the least-squares analysis of
semilogarithmic plots of remaining activity [E]/[E]0 against time
(Equation (2)). They are related to KI and ki by Equation (3).
lnð½E =½E 0Þ¼kobst ð2Þ
kobs ¼
ki ½I 0
k1 ½I 0
ð3Þ
At low inhibitor concentrations, the ratio ki/KI was obtained as
kobs/[I]0. The enzyme, coumarin derivative and substrate concen-
trations were: [LMW-uPA]0¼12nM,[ I ] 0¼0.5–10mM,[ S ] 0¼30mM;
[PM]0¼28nM, [I]0¼2.8–28.3mM and [S]0¼0.14mM. In the
progress curve method, the substrate competes with the inhibitor
and the kinetic parameters are determined as previously described
(Doucet et al, 1999). The enzyme, substrate and coumarin
derivative concentrations were: [HLE]0¼30nM, [S]0¼100mM
and [I]0¼0.05–70mM.
The products resulting from the spontaneous hydrolysis of
compounds 1–4and 7 obtained by 18h incubation at pH 7.5 were
also checked for a possible inhibitory effect against the purified
enzymes MMP-2 and MMP-9 (50pM and 1nM, respectively;
[S]0¼220mM), LMW-uPA and HMW-uPA (12 and 15nM, respec-
tively; [S]0¼30mM) and PM (17nM, [S]0¼270mM).
RESULTS
Synthetic coumarin derivatives reduce HT1080
fibrosarcoma cells invasion
To determine whether coumarin derivatives could reduce the
invasive behaviour of tumour cells, we measured the ability of cells
treated or not with the coumarin derivative to pass through type
IV collagen-coated Transwell cell culture inserts (chemoinvasion
assay). Cell invasion in the absence of coumarin derivative was
considered as 100% (Figure 2A and B, Control). The results were
compared to those observed with a well-known hydroxamate-
MMP inhibitor: GI 129471, used at 1mM concentration as reference
compound. In such a chemoinvasion assay, this reference
compound led to a 60% inhibition of HT1080 cell invasion.
Coumarin derivatives 1–4 (Figure 2A) reduced HT1080 cell
migration in a dose-dependent manner. The unsubstituted
derivative 1 (Y¼H) reduced the invasion by 50% at 1mM and
65% at 10mM. The 6-methyl 2 (Y¼CH3) and the 6-acetoxymethyl 4
(Y¼CH2OCOCH3) coumarin affected the invasion in a similar
manner. At 1mM, both compounds led to a 50% inhibition, and at
10mM, a 70 and 90% inhibition were observed for the methyl 2 and
the acetoxymethyl 4 derivatives, respectively. In contrast, cell
invasiveness was not markedly affected by addition of the
6-chloromethyl-substituted derivative 3 (Y¼CH2Cl) (only 30%
invasion inhibition at 10mM). Thus, these data indicate that an
acetoxymethyl group in the 6-position gave rise to better inhibition
of cell invasion (Figure 2A).
We next synthesised the 3-phenyl (5) and the 3-halogenophenyl
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate deriva-
tives 6–8. The different halogen atoms (F, Cl, Br or I) present
on the 30-position gave rise to different effects on cell invasion
(Figure 2B). Addition of the unsubstituted derivative 5 (X0 ¼H)
has a lower inhibitory effect on cell chemoinvasion than that
observed with GI 129471. Indeed, when this derivative was used at
1mM, a 30% inhibition of cell invasion was observed. At 10mM,i t
gave rise to a similar inhibition (50–60%) as that observed by
using the reference compound at 1mM. Substitution by a halogen
atom improved the inhibitory capacity of coumarin derivatives as
compared to the nonsubstituted one. Addition of chloro (X0 ¼Cl,
compound 4) and iodo (X0 ¼I, compound 8) derivatives at 1mM
led to an inhibition quite similar to that observed with the
reference compound. Interestingly, fluoro (X0 ¼F, compound 6)
and bromo (X0 ¼Br, compound 7) derivatives appeared more
potent, inducing an 80% inhibition at similar concentration.
Moreover, chloro (compound 4) and bromo (compound 7)
derivatives used at 10mM dramatically decreased the cell invasive-
ness (790% invasion inhibition).
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sSince these two products (compounds 4 and 7) appeared to be
very potent inhibitors of cell invasion, their anti-invasion and
anticancer capacities were further studied in vitro and in vivo.W e
compared the ability of cells treated or not with the two selected
coumarin derivatives to invade through type IV collagen-coated
filters (chemoinvasion) and through uncoated filters (chemotaxis).
Chemoinvasion corresponds to the capacity to invade through an
extracellular matrix, while chemotaxis relies on the ability to
migrate in response to a chemotactic factor. Addition of the chloro
derivative 4 caused a potent and dose-dependent decrease of
HT1080 cell chemoinvasion confirming the results reported in
Figure 2B. In the chemotaxis assay, a similar dose response
inhibitory effect was observed (20% inhibition at 0.1mM, 50%
inhibition at 1mM and 80% at 10mM). In contrast, cell migration
through uncoated filters was not markedly affected by the
reference compound at 1mM (20–30% chemotaxis inhibition vs
60% inhibition of chemoinvasion) (Figure 3A). Although the
bromo derivative (compound 7) reduced cell invasion and
migration in a dose-dependent manner, this compound was a
more potent inhibitor of chemoinvasion than chemotaxis
(Figure 3B). Its effect on chemotaxis at 1mM was similar to that
observed with the reference compound.
These effects of both compounds could not be ascribed to a
modulation of cell adhesion or cell proliferation. Indeed,
independent of the presence of coumarin derivatives, 100% of cell
adhesion to plastic, type IV collagen or matrigel was reached
within 7h 30min or 2h, respectively. Similarly, cell proliferation
was not affected by both compounds (data not shown).
Enzymatic studies
To further gain insights into the characterisation of the selected
coumarin derivatives tested (4 and 7), we have evaluated their
activity against serine proteases and MMPs released by HT1080
cells. We first performed plasminogen and gelatin zymographic
analysis on HT1080 cell conditioned media. Plasminogen activator
activity was detected in all samples. Densitometric analysis of
zymograms revealed greater amounts of HMW-uPA than LMW-
uPA. Gelatin zymography demonstrated the presence of pro-MMP-
2 (66kDa), pro-MMP-9 (92kDa), two MMP-2 activated forms (62
and 59kDa) and a 120kDa gelatinolytic species (Figure 4). The
latter activity was attributed to a complex formed between TIMP-1
and pro-MMP-9 (Maquoi et al, 1999). The addition of compounds
4 or 7 to the conditioned culture medium did not abrogate neither
the HMW- and LMW-uPA nor the gelatinolytic activities.
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Figure 2 Synthetic coumarin derivatives reduce HT1080 fibrosarcoma
cells invasion. HT1080 chemoinvasion was evaluated in Transwell cell
culture inserts coated with type IV collagen. HT1080 cells (6 10
4) were
seeded in the absence (control) or presence of different concentrations of
coumarinic inhibitor (0.1, 1 and 10mM) and the number of cells that have
migrated was determined by visually counting the number of cells present
on the lower side of the filters, as described in Materials and Methods: (A)
3-chlorophenyl 2-oxo-2H-1-benzopyran-3-carboxylate derivatives diver-
sally substituted in the 6-position and (B) 6-acetoxymethyl-2-oxo-2H-1-
benzopyran-3-carboxylic acid derivatives.
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Figure 3 Effect of synthetic coumarin derivatives on HT1080 fibrosar-
coma cell invasion. Chemoinvasion and chemotaxis were evaluated in
Transwell cell culture inserts coated or not with type IV collagen,
respectively. HT1080 cells (6 10
4) were seeded in the absence (control)
or presence of the coumarin inhibitor (0.1, 1 and 10mM) and the number of
cells that have migrated was determined by visually counting the number of
cells present on the lower side of the filters: (A) 3-chlorophenyl 6-
acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate and (B) 3-bromo-
phenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate.
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selected compounds to that of other coumarin derivatives against
purified enzymes (Table 3). It was previously demonstrated that
the 6-chloromethyl derivative (compound 3) acted as a suicide
substrate leading to enzyme irreversible inhibition of a-CT,
whereas HLE was transiently inactivated through the formation
of a stable acyl-enzyme (Pochet et al, 1996, 2000). We found here
that LMW-uPA and PM were inactivated by compound 3 (Table 3).
No reactivation of inhibited LMW-uPA was observed either
spontaneously after 18h incubation or after treatment with
NH2OH (pH 7.5, 251C) demonstrating that the observed irrever-
sible process is not because of the formation of a stable acyl-
enzyme. Hydroxylamine is known to cleave acyl-enzymes (Doucet
et al, 1999). It was verified that no noticeable denaturation of
untreated LMW-uPA occurred during the above experiments.
Presumably, compound 3 inactivates LMW-uPA according to the
same mechanism as demonstrated for the inactivation of a-CT
(suicide inhibition; Pochet et al, 1996). The closely related
dihydrocoumarins (3,4-dihydro-3,4-dibromo-6-bromomethylcou-
marin and 3,4-dihydro-3-benzyl-6-chloromethylcoumarin) were
demonstrated to act as suicide substrates of LMW- and HMW-uPA
with modification of the active site His57 (Reboud-Ravaux et al,
1982; Reboud-Ravaux and Desvages, 1984). In sharp contrast,
purified LMW-uPA was not inactivated by compounds 1, 2, 4 and
7. In addition, the activities of purified HMW-uPA, PM, MMP-2
and MMP-9 were not affected by the presence of compounds 4 and
7, or of their hydrolysis products. Surprisingly, the 3-chlorophenyl
6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate 3, which
possesses an inhibitory potency against uPA and PM, did not
markedly decrease the cell invasiveness. It is worth noting that the
two compounds (4 and 7), which markedly decreased the cell
invasiveness at 10mM (Y¼CH2OCOCH3;X 0 ¼Cl and Br), were
unable to act as uPA, PM or MMPs inhibitors.
Effect of coumarin derivatives on tumour growth in vivo
We next investigated the influence of the two selected compounds
4 and 7 (Y¼CH2OCOCH3;X 0 ¼Cl and Br) on the development
of tumours induced by the injection into nude mice of human
breast adenocarcinoma and fibrosarcoma cells. Treatment of
mice with bromo derivative (compound 7) was found to reduce
both the incidence (log Rank test, Po0.004) and growth of
tumours induced by sc injection of HT1080 cells (Figure 5A and
B). After cell inoculation, a tumour incidence of 50% was reached
after 26 days in control mice or animals treated with the chloro
derivative, and after 48 days in animals treated with the
bromo derivative (Figure 5A). These data demonstrate that the
bromo derivative delayed the apparition of tumours. In addi-
tion, this compound significantly reduced the tumour growth
(Figure 5B), since the tumour volume reached at the end of the
assay was markedly reduced in animals treated with compound 7
(ANOVA analysis, Po0.05). In sharp contrast, the chloro
derivative did not significantly affect tumour growth.
The effects of both compounds were also evaluated on the
tumorigenicity of mammary MDA-MB231 cells. The MDA-MB231
cell inoculation led to 100% tumours within 2–3 weeks. While the
bromo derivative did not affect tumour incidence, it again reduced
Pro-MMP−9
Pro-MMP−2
92
66
62
kDa
Figure 4 Matrix metalloprotease production by HT1080 cells analysed
by gelatin zymography of the conditioned medium. The 59 and 120kDa
forms were present as traces.
Table 3 Kinetic parameters for the inactivation of several serine proteases by 3-halogenophenyl 2-oxo-
2H-1-benzopyran-3-carboxylate derivatives diversely substituted in the 6-position
O O
O
O X′
Y
ki/KI or kobs/[I] (M
 1s
 1)
No. Y X0 a-CT HLE LMW-uPA Plasmin
1H 3 0-Cl o500
a 610
a NI ND
2C H 3 30-Cl 9400
a 1100
a NI ND
3C H 2Cl 30-Cl 762700
b 630
b 336 600
4C H 2OCOCH3 30-Cl 20000
a 1440
a NI NI
7C H 2OCOCH3 30-Br ND 2190 NI NI
NI=no inhibition, ND=not determined. High-molecular-weight two-chain urokinase plasminogen activator, MMP-2 and
MMP-9 are not inhibited by compounds 4 and 7. Standard errors are less than 15%.
aData from Pochet et al (2000).
bData
from Pochet et al (1996).
Inhibition of cancer cell invasion
I Kempen et al
1116
British Journal of Cancer (2003) 88(7), 1111–1118 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
ssignificantly tumour growth (Figure 6). (ANOVA analysis,
Po0.05).
DISCUSSION
This paper describes the evaluation of the anti-invasive properties
of recently developed synthetic coumarin derivatives. The starting
point of this work was the observation that 2-oxo-2H-1-
benzopyran-3-carboxylic acid derivatives act as potent inhibitors
of diverse serine proteases such as a-CT, HLE and THR (Pochet
et al, 1996, 2000; Doucet et al, 1999). Owing to possible implication
of serine proteases such as uPA and PM in the metastatic process
(Andreasen et al, 1997; Schmitt et al, 2000), a selection of
previously described coumarins as well as new synthetic deriva-
tives was therefore examined in vitro and in vivo on different
experimental models. Thus, in order to highlight possible antic-
ancer properties linked to their expected profile as protease
inhibitors, the inhibitory capacity of the different compounds was
determined in vitro on several serine proteases and MMPs (MMP-2
and MMP-9) (Egeblad and Werb, 2002). Moreover, chemoinvasion
and chemotaxis in vitro assays as well as in vivo tumorigenic
assays were conducted on nude mice, inoculated with HT1080 or
MDA-MB231 cells.
Using noncytotoxic concentrations of compounds, our studies
illustrated that some coumarin derivatives markedly inhibited the
HT1080 cell invasiveness. The inhibition capacity varied according
to the substituent present in the 6-position of the coumarin, and
according to the nature of the halogen atom in the 3-position of the
phenyl ring. In general, substitution by a halogen atom
(particularly, a chlorine or a bromine atom) in the ‘meta’ position
of the phenyl ring relative to the ester oxygen atom of 2-oxo-2H-1-
benzopyran-3-carboxylate led to a better anti-invasive effect than
that observed in the absence of any substituent. In the same way,
an acetoxymethyl or a methyl group in the 6-position conferred an
improved effect.
It is worth noting that 3-chlorophenyl 6-acetoxymethyl-2-oxo-
2H-1-benzopyran-3-carboxylate (compound 4) has almost the
same potent inhibitory activity on cellular invasion (chemoinva-
sion) and on cell migration (chemotaxis). In sharp contrast, the
corresponding 3-bromo derivative (compound 7) led to a low
inhibitory effect on chemotaxis, similar to that observed with GI
129471 used as reference compound (30% inhibition at 1mM).
Interestingly, the bromo derivative was more potent in the
chemoinvasion assay than the reference compound and the
chloro-substituted analogue. These data emphasise the interest of
the bromo derivative as an anti-invasive inhibitor. On the
contrary, the chloro derivative which affected both chemoinvasion
and chemotaxis is likely to modulate cell mobility in a manner
independent of a protease inhibition. In accordance with these in
vitro observations, our in vivo study in two experimental models
demonstrates that only the bromo derivative markedly affected
tumour growth. It reduced both the incidence and the growth of
tumour induced by HT1080 cell injection. Furthermore, it affected
the growth of more aggressive breast adenocarcinoma MDA-
MB231 derived tumours.
The two selected coumarin derivatives 4 and 7 were not found to
act as an uPA, PM, MMP-2 or MMP-9 inhibitor. Moreover, the
coumarin derivative 3, which was found to be a strong inacti-
vator of a-CT and THR and which possessed an inhibitory
potency towards uPA, did not markedly decrease cell invasive-
ness. Thus, the observed activity of the coumarin derivatives
on HT1080 cell invasion could not be ascribed to their
inhibitory activity against the enzymes tested. Both compounds
were found to be unable to inhibit the angiogenesis evaluated in
the aortic ring assay (data not shown) according to the procedure
previously described (Blacher et al, 2001; Masson et al, 2002).
Consequently, further experimental investigations are required to
determine the exact mechanism of action of the bromo coumarin
derivative and its biological target. For example, the recently
described MT-SPS which are membrane-bound serine proteases
implicated in tumorigenesis are possible targets for protease
inhibitors like coumarins (Takeuchi et al, 2000; Hooper et al,
2001). In the light of our in vivo and in vitro results, the bromo
coumarin derivative appears to be very promising as potential
antitumoral agent. To the best of our knowledge, this study
provides for the first time evidence that a coumarin derivative
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Figure 5 (A) Incidence of tumours induced by subcutaneous (s.c.)
injection of HT1080 cells (percent of animals bearing tumour higher than
80mm
3). (B) Growth curves of tumour formed, in nude mice (n¼6), after
s.c. injection of HT1080 cells (1 10
6) mixed with matrigel. The mice were
examined twice a week for tumour appearance and measurement.
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Figure 6 Growth curves of tumour formed, in nude mice (n¼6), after
s.c. injection of MDA-MB231 cells (1 10
6) mixed with matrigel. The mice
were examined twice a week for tumour appearance and measurement.
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sdisplays marked anti-invasive properties in vitro and antitumour
activities in vivo.
The disappointment of MMP inhibitors in clinical trials as a
result of the expression of a high toxicity (Coussens et al, 2002)
emphasises the importance of a better elucidation of the
mechanism of inhibition action in vitro and in vivo. Although
coumarin derivatives might constitute an alternative to MMP
inhibitors as anticancer agents, further biological investigations
are required before any clinical trial.
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